Published in Catheter Cardiovasc Interv on July 04, 2014
Outcomes With the Use of the Retrograde Approach for Coronary Chronic Total Occlusion Interventions in a Contemporary Multicenter US Registry. Circ Cardiovasc Interv (2016) 1.39
Clinical Utility of the Japan-Chronic Total Occlusion Score in Coronary Chronic Total Occlusion Interventions: Results from a Multicenter Registry. Circ Cardiovasc Interv (2015) 1.05
Effect of Previous Failure on Subsequent Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention (from a Contemporary Multicenter Registry). Am J Cardiol (2016) 0.81
Predictive scores in chronic total occlusions percutaneous recanalization: only fashionable or really useful? J Thorac Dis (2016) 0.79
Use of antegrade dissection re-entry in coronary chronic total occlusion percutaneous coronary intervention in a contemporary multicenter registry. Int J Cardiol (2016) 0.76
Hybrid PCI: the optimal combination for chronic total occlusions due to in-stent restenosis? Catheter Cardiovasc Interv (2014) 0.75
Effect of Lesion Age on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary US Multicenter Registry. Can J Cardiol (2016) 0.75
Higher plasma level of STIM1, OPG are correlated with stent restenosis after PCI. Int J Clin Exp Med (2015) 0.75
Use of Intravascular Imaging During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. J Am Heart Assoc (2016) 0.75
Impact of diabetes mellitus on acute outcomes of percutaneous coronary intervention in chronic total occlusions: insights from a US multicentre registry. Diabet Med (2016) 0.75
In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol (2010) 2.85
In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan). JACC Cardiovasc Interv (2010) 2.36
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol (2009) 2.29
A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv (2012) 1.95
Incidence and predictors of late total occlusion following coronary stenting. Catheter Cardiovasc Interv (2003) 1.61
A novel approach to the management of occlusive in-stent restenosis (ISR). EuroIntervention (2014) 0.98
Use of the Crossboss catheter in coronary chronic total occlusion due to in-stent restenosis. Catheter Cardiovasc Interv (2011) 0.96
Success, safety, and mechanisms of failure of percutaneous coronary intervention for occlusive non-drug-eluting in-stent restenosis versus native artery total occlusion. Am J Cardiol (2005) 0.92
Management of total restenotic occlusions. EuroIntervention (2009) 0.91
Contemporary outcomes of percutaneous intervention in chronic total coronary occlusions due to in-stent restenosis. Cardiovasc Revasc Med (2010) 0.89
Dislodged and mechanically distorted stent stuck within a previously implanted drug-eluting stent. Heart Vessels (2012) 0.86
Serial gray scale intravascular ultrasound findings in late drug-eluting stent restenosis. Am J Cardiol (2012) 0.86
Successful bypass restenting across the struts of an occluded subintimal stent in chronic total occlusion using a retrograde approach. Catheter Cardiovasc Interv (2013) 0.85
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (2003) 16.14
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol (2009) 5.66
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol (2012) 3.98
The role of open-lung biopsy in ARDS. Chest (2004) 3.46
Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv (2010) 3.24
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 2.91
Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol (2012) 2.85
Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation (2003) 2.77
Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol (2013) 2.64
Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 65 studies. JACC Cardiovasc Interv (2013) 2.54
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol (2008) 2.54
Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol (2009) 2.53
Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience. Int J Radiat Oncol Biol Phys (2009) 2.39
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol (2009) 2.29
Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol (2009) 2.26
A universal carrier test for the long tail of Mendelian disease. Reprod Biomed Online (2010) 2.21
Improvement in survival following successful percutaneous coronary intervention of coronary chronic total occlusions: variability by target vessel. JACC Cardiovasc Interv (2008) 2.20
Frequency and risk of noncardiac surgery after drug-eluting stent implantation. Catheter Cardiovasc Interv (2011) 2.18
Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med (2011) 2.11
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood (2005) 2.08
The effectiveness of mandibular distraction in improving airway obstruction in the pediatric population. Plast Reconstr Surg (2014) 2.04
Retrograde techniques and the impact of operator volume on percutaneous intervention for coronary chronic total occlusions an early U.S. experience. JACC Cardiovasc Interv (2009) 2.03
Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation (2002) 2.00
The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. J Am Coll Cardiol (2010) 1.98
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med (2009) 1.98
A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv (2012) 1.95
Successful recanalization of chronic total occlusions is associated with improved long-term survival. JACC Cardiovasc Interv (2012) 1.93
Impact of prior coronary artery bypass graft surgery on chronic total occlusion revascularisation: insights from a multicentre US registry. Heart (2013) 1.89
Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant (2010) 1.85
Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology (2011) 1.85
Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology (2013) 1.83
Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J (2014) 1.82
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol (2010) 1.80
Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J (2006) 1.73
Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J Am Coll Cardiol (2013) 1.72
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther (2008) 1.69
Saphenous vein graft intervention. JACC Cardiovasc Interv (2011) 1.69
Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). JACC Cardiovasc Interv (2010) 1.67
Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: insights from the Dartmouth Dynamic Registry. Catheter Cardiovasc Interv (2008) 1.67
Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv (2011) 1.66
Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation (2004) 1.65
Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol (2004) 1.64
Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res (2006) 1.61
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation (2005) 1.60
Mechanical ventilation and air leaks after lung biopsy for acute respiratory distress syndrome. Ann Thorac Surg (2006) 1.59
Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr (2009) 1.58
Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical, and cost-utilization outcomes. Catheter Cardiovasc Interv (2013) 1.56
Endocarditis associated with antineutrophil cytoplasmic antibodies: a case report and review of the literature. Clin Rheumatol (2006) 1.55
Percutaneous coronary intervention use in the United States: defining measures of appropriateness. JACC Cardiovasc Interv (2012) 1.54
Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease. Am J Epidemiol (2002) 1.53
Frequency and outcomes of aortocoronary dissection during percutaneous coronary intervention of chronic total occlusions: a case series and systematic review of the literature. Catheter Cardiovasc Interv (2013) 1.53
Association of periodontitis with rheumatoid arthritis: a pilot study. J Periodontol (2010) 1.53
Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer (2007) 1.52
Comparison by meta-analysis of drug-eluting stents and bare metal stents for saphenous vein graft intervention. Am J Cardiol (2010) 1.52
Quality of life benefits of percutaneous coronary intervention for chronic occlusions. Catheter Cardiovasc Interv (2013) 1.52
Use of drug-eluting stents for chronic total occlusions: a systematic review and meta-analysis. Catheter Cardiovasc Interv (2011) 1.51
Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv (2010) 1.51
PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov (2011) 1.50
Temporal trends of fluoroscopy time and contrast utilization in coronary chronic total occlusion revascularization: insights from a multicenter united states registry. Catheter Cardiovasc Interv (2014) 1.48